Cargando…

Evaluation of Strategies to Fight COVID-19: The French Paradigm

(1) Background: We collected COVID-19 mortality data and the age distribution of the deceased in France and other European countries, as well as specifically in the cities of Paris and Marseille, and compared them. (2) Methods: Data on mortality related to COVID-19 and the associated age distributio...

Descripción completa

Detalles Bibliográficos
Autores principales: Giraud-Gatineau, Audrey, Gautret, Philippe, Colson, Philippe, Chaudet, Hervé, Raoult, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268313/
https://www.ncbi.nlm.nih.gov/pubmed/34209087
http://dx.doi.org/10.3390/jcm10132942
_version_ 1783720328996847616
author Giraud-Gatineau, Audrey
Gautret, Philippe
Colson, Philippe
Chaudet, Hervé
Raoult, Didier
author_facet Giraud-Gatineau, Audrey
Gautret, Philippe
Colson, Philippe
Chaudet, Hervé
Raoult, Didier
author_sort Giraud-Gatineau, Audrey
collection PubMed
description (1) Background: We collected COVID-19 mortality data and the age distribution of the deceased in France and other European countries, as well as specifically in the cities of Paris and Marseille, and compared them. (2) Methods: Data on mortality related to COVID-19 and the associated age distribution were collected from government institutions in various European countries. In France, data were obtained from INSEE and Santé Publique France. All-cause mortality was also examined in order to study potential excess mortality using EuroMOMO. The Marseille data came from the epidemiological surveillance system. (3) Results: France is one of the European countries most impacted by COVID-19. Its proportion of deaths in people under 60 years of age is higher (6.5%) than that of Italy (4.6%) or Spain (4.7%). Excess mortality (5% more deaths) was also observed. Ile-de-France and the Grand-Est are the two French regions with the highest mortality. The proportion of deaths in the under-60 age group was considerable in Ile-de-France (9.9% vs. 4.5% in the Southern region). There are significantly higher numbers of patients hospitalized, in intensive care and deceased in Paris than in Marseille. (4) Conclusions: No patient management, i.e., from screening to diagnosis, including biological assessment and clinical examination, likely explains the high mortality associated with COVID-19.
format Online
Article
Text
id pubmed-8268313
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82683132021-07-10 Evaluation of Strategies to Fight COVID-19: The French Paradigm Giraud-Gatineau, Audrey Gautret, Philippe Colson, Philippe Chaudet, Hervé Raoult, Didier J Clin Med Article (1) Background: We collected COVID-19 mortality data and the age distribution of the deceased in France and other European countries, as well as specifically in the cities of Paris and Marseille, and compared them. (2) Methods: Data on mortality related to COVID-19 and the associated age distribution were collected from government institutions in various European countries. In France, data were obtained from INSEE and Santé Publique France. All-cause mortality was also examined in order to study potential excess mortality using EuroMOMO. The Marseille data came from the epidemiological surveillance system. (3) Results: France is one of the European countries most impacted by COVID-19. Its proportion of deaths in people under 60 years of age is higher (6.5%) than that of Italy (4.6%) or Spain (4.7%). Excess mortality (5% more deaths) was also observed. Ile-de-France and the Grand-Est are the two French regions with the highest mortality. The proportion of deaths in the under-60 age group was considerable in Ile-de-France (9.9% vs. 4.5% in the Southern region). There are significantly higher numbers of patients hospitalized, in intensive care and deceased in Paris than in Marseille. (4) Conclusions: No patient management, i.e., from screening to diagnosis, including biological assessment and clinical examination, likely explains the high mortality associated with COVID-19. MDPI 2021-06-30 /pmc/articles/PMC8268313/ /pubmed/34209087 http://dx.doi.org/10.3390/jcm10132942 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Giraud-Gatineau, Audrey
Gautret, Philippe
Colson, Philippe
Chaudet, Hervé
Raoult, Didier
Evaluation of Strategies to Fight COVID-19: The French Paradigm
title Evaluation of Strategies to Fight COVID-19: The French Paradigm
title_full Evaluation of Strategies to Fight COVID-19: The French Paradigm
title_fullStr Evaluation of Strategies to Fight COVID-19: The French Paradigm
title_full_unstemmed Evaluation of Strategies to Fight COVID-19: The French Paradigm
title_short Evaluation of Strategies to Fight COVID-19: The French Paradigm
title_sort evaluation of strategies to fight covid-19: the french paradigm
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268313/
https://www.ncbi.nlm.nih.gov/pubmed/34209087
http://dx.doi.org/10.3390/jcm10132942
work_keys_str_mv AT giraudgatineauaudrey evaluationofstrategiestofightcovid19thefrenchparadigm
AT gautretphilippe evaluationofstrategiestofightcovid19thefrenchparadigm
AT colsonphilippe evaluationofstrategiestofightcovid19thefrenchparadigm
AT chaudetherve evaluationofstrategiestofightcovid19thefrenchparadigm
AT raoultdidier evaluationofstrategiestofightcovid19thefrenchparadigm